DEPARTMENT OF HEALTH & HUMAN SERVICES **Public Health Service**

Food and Drug Administration
Rockville MD 20857

NDA 18-045/S-016

Pharmacia and Upjohn
7000 Portage Road
Mailstop 0636-298-113
Kalamazoo, MI 49001-0199

Attention: Gregory Brier
Regulatory Manager

Dear Mr. Brier:

Please refer to your supplemental new drug application dated October 28, 1997, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Emcyt (estramustine phosphate sodium) Capsules.

We acknowledge receipt of your submission dated March 16, 1998.

This "Changes Being Effected" supplemental new drug application provides for revisions to the **General** subsection of the **PRECAUTIONS** section which was expanded to include the following statements:

- "Allergic reactions and angioedema at times involving the airway have been reported."
- "Gynecomastia and impotence are known estrogenic effects."

Additionally, the revisions affect the **Laboratory Tests** subsection of the **PRECAUTIONS** section as follows:

- Delete "...but have seldom been severe enough to require cessation of therapy."
- Add "Emcyt may depress testosterone levels."

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the submitted final printed labeling (package insert submitted March 16, 1998, immediate container and carton labels submitted March 16, 1998). Accordingly, the supplemental application is approved effective on the date of this letter.

The Division has instituted a policy to standardize the package insert REFERENCES section. At the next printing please add the reference below to your current references:

> ONS Clinical Practice Committee. Cancer Chemotherapy Guidelines and Recommendations for Practice Pittsburgh, Pa: Oncology Nursing Society; 1999:32-41.

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21CFR 314.80 and 314.81.

If you have any questions, call Brenda Atkins, Project Manager, at (301) 594-5767.

Sincerely,

{See appended electronic signature page}

Richard Pazdur, M.D.
Director
Division of Oncology Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Richard Pazdur

1/18/02 06:09:12 PM